Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ronald L. Dalman is active.

Publication


Featured researches published by Ronald L. Dalman.


Journal of Vascular Surgery | 2009

The care of patients with an abdominal aortic aneurysm: The Society for Vascular Surgery practice guidelines

Elliot L. Chaikof; David C. Brewster; Ronald L. Dalman; Michel S. Makaroun; Karl A. Illig; Gregorio A. Sicard; Carlos H. Timaran; Gilbert R. Upchurch; Frank J. Veith

The Clinical Practice Council of the Society for Vascular Surgery charged a writing committee with the task of updating practice guidelines, initally published in 2003, for surgeons and physicians who are involved in the preoperative, operative, and postoperative care of patients with abdominal aortic aneurysms (AAA). This document provides recommendations for evaluating the patient, including risk of aneurysm rupture and associated medical co-morbidities, guidelines for selecting surgical or endovascular intervention, intraoperative strategies, perioperative care, long-term follow-up, and treatment of late complications. Decision making related to the care of patients with AAA is complex. Aneurysms present with varying risks of


American Journal of Human Genetics | 2009

Mutations in Smooth Muscle Alpha-Actin (ACTA2) Cause Coronary Artery Disease, Stroke, and Moyamoya Disease, Along with Thoracic Aortic Disease

Dong Chuan Guo; Christina L. Papke; Van Tran-Fadulu; Ellen S. Regalado; Nili Avidan; Ralph J. Johnson; Dong H. Kim; Hariyadarshi Pannu; Marcia C. Willing; Elizabeth Sparks; Reed E. Pyeritz; Michael Singh; Ronald L. Dalman; James C. Grotta; Ali J. Marian; Eric Boerwinkle; Lorraine Frazier; Scott A. LeMaire; Joseph S. Coselli; Anthony L. Estrera; Hazim J. Safi; Sudha Veeraraghavan; Donna M. Muzny; David A. Wheeler; James T. Willerson; Robert Yu; Sanjay Shete; Steven E. Scherer; C. S. Raman; L. Maximilian Buja

The vascular smooth muscle cell (SMC)-specific isoform of alpha-actin (ACTA2) is a major component of the contractile apparatus in SMCs located throughout the arterial system. Heterozygous ACTA2 mutations cause familial thoracic aortic aneurysms and dissections (TAAD), but only half of mutation carriers have aortic disease. Linkage analysis and association studies of individuals in 20 families with ACTA2 mutations indicate that mutation carriers can have a diversity of vascular diseases, including premature onset of coronary artery disease (CAD) and premature ischemic strokes (including Moyamoya disease [MMD]), as well as previously defined TAAD. Sequencing of DNA from patients with nonfamilial TAAD and from premature-onset CAD patients independently identified ACTA2 mutations in these patients and premature onset strokes in family members with ACTA2 mutations. Vascular pathology and analysis of explanted SMCs and myofibroblasts from patients harboring ACTA2 suggested that increased proliferation of SMCs contributed to occlusive diseases. These results indicate that heterozygous ACTA2 mutations predispose patients to a variety of diffuse and diverse vascular diseases, including TAAD, premature CAD, ischemic strokes, and MMD. These data demonstrate that diffuse vascular diseases resulting from either occluded or enlarged arteries can be caused by mutations in a single gene and have direct implications for clinical management and research on familial vascular diseases.


Circulation | 2008

Medical Management of Small Abdominal Aortic Aneurysms

B. Timothy Baxter; Michael C. Terrin; Ronald L. Dalman

Abdominal aortic aneurysm is a common condition that may be lethal when it is unrecognized. Current guidelines suggest repair as the aneurysm diameter reaches 5.0 to 5.5 cm. Most aortic aneurysms are detected incidentally when imaging is done for other purposes or through screening programs. Ninety percent of these aneurysms are below the threshold for intervention at the time of detection. A number of studies have sought to determine factors that lead to progression of aneurysmal disease that might be amenable to intervention during this period of observation. We review these studies and make recommendations for the medical management of small abdominal aortic aneurysms. On the basis of our current knowledge of the causes of aneurysm, a number of approaches have been proposed to prevent progression of aneurysmal disease. These include hemodynamic management, inhibition of inflammation, and protease inhibition. The American College of Cardiology/American Heart Association clinical practice guidelines rules of evidence have helped to define strength of evidence to support these approaches. Level A evidence (from large randomized trials) is available to indicate that observation of small aneurysms in men is safe up to a size of 5.5 cm and that propranolol does not inhibit aneurysm expansion. Level B evidence (from small randomized trials) suggests that roxithromycin or doxycycline will decrease the rate of aneurysm expansion. A number of studies agree that tobacco use is associated with an increased rate of aneurysm expansion. Level B and C evidence is available to suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may inhibit aneurysm expansion. There are animal data but no human data demonstrating that angiotensin-converting enzyme inhibitors or losartan, an angiotensin receptor blocker, will decrease the rate of AAA expansion. A pharmacological agent without important side effects that inhibited aneurysm expansion could change current approaches to aneurysm treatment. Additional studies are needed to clarify the potential role of doxycycline, roxithromycin, and statin therapy in the progression of aneurysmal disease.


Journal of the National Cancer Institute | 2008

Decreased Cancer Risk After Iron Reduction in Patients With Peripheral Arterial Disease: Results From a Randomized Trial

Leo R. Zacharski; Bruce K. Chow; Paula S. Howes; Galina Shamayeva; John A. Baron; Ronald L. Dalman; David J. Malenka; C. Keith Ozaki; Philip W. Lavori

BACKGROUND Excess iron has been implicated in cancer risk through increased iron-catalyzed free radical-mediated oxidative stress. METHODS A multicenter randomized, controlled, single-blinded clinical trial (VA Cooperative Study #410) tested the hypothesis that reducing iron stores by phlebotomy would influence vascular outcomes in patients with peripheral arterial disease. Patients without a visceral malignancy in the last 5 years (n = 1277) were randomly assigned to control (n = 641) or iron reduction (n = 636). Occurrence of new visceral malignancy and cause-specific mortality data were collected prospectively. Cancer and mortality outcomes in the two arms were compared using intent-to-treat analysis with a Cox proportional hazards regression model. Statistical tests were two-sided. RESULTS Patients were followed up for an average of 4.5 years. Ferritin levels were similar in both groups at baseline but were lower in iron reduction patients than control patients across all 6-month visits (mean = 79.7 ng/mL, 95% confidence interval [CI] = 73.8 to 85.5 ng/mL vs 122.5 ng/mL, 95% CI = 115.5 to 129.5 ng/mL; P < .001). Risk of new visceral malignancy was lower in the iron reduction group than in the control group (38 vs 60, hazard ratio [HR] = 0.65, 95% CI = 0.43 to 0.97; P = .036), and, among patients with new cancers, those in the iron reduction group had lower cancer-specific and all-cause mortality (HR = 0.39, 95% CI = 0.21 to 0.72; P = .003; and HR = 0.49, 95% CI = 0.29 to 0.83; P = .009, respectively) than those in the control group. Mean ferritin levels across all 6-monthly visits were similar in patients in the iron reduction and control groups who developed cancer but were lower among all patients who did not develop cancer than among those who did (76.4 ng/mL, 95% CI = 71.4 to 81.4 ng/mL, vs 127.1 ng/mL, 95% CI = 71.2 to 183.0 ng/mL; P = .017). CONCLUSIONS Iron reduction was associated with lower cancer risk and mortality. Further studies are needed to define the role of body iron in cancer risk.


Matrix Biology | 2008

The three−dimensional micro− and nanostructure of the aortic medial lamellar unit measured using 3D confocal and electron microscopy imaging

Mary K. O'Connell; Sushila Murthy; Samson Phan; Chengpei Xu; JoAnn Buchanan; Ryan L. Spilker; Ronald L. Dalman; Christopher K. Zarins; Winfried Denk; Charles A. Taylor

Changes in arterial wall composition and function underlie all forms of vascular disease. The fundamental structural and functional unit of the aortic wall is the medial lamellar unit (MLU). While the basic composition and organization of the MLU is known, three-dimensional (3D) microstructural details are tenuous, due (in part) to lack of three-dimensional data at micro- and nano-scales. We applied novel electron and confocal microscopy techniques to obtain 3D volumetric information of aortic medial microstructure at micro- and nano-scales with all constituents present. For the rat abdominal aorta, we show that medial elastin has three primary forms: with approximately 71% of total elastin as thick, continuous lamellar sheets, 27% as thin, protruding interlamellar elastin fibers (IEFs), and 2% as thick radial struts. Elastin pores are not simply holes in lamellar sheets, but are indented and gusseted openings in lamellae. Smooth muscle cells (SMCs) weave throughout the interlamellar elastin framework, with cytoplasmic extensions abutting IEFs, resulting in approximately 20 degrees radial tilt (relative to the lumen surface) of elliptical SMC nuclei. Collagen fibers are organized as large, parallel bundles tightly enveloping SMC nuclei. Quantification of the orientation of collagen bundles, SMC nuclei, and IEFs reveal that all three primary medial constituents have predominantly circumferential orientation, correlating with reported circumferentially dominant values of physiological stress, collagen fiber recruitment, and tissue stiffness. This high resolution three-dimensional view of the aortic media reveals MLU microstructure details that suggest a highly complex and integrated mural organization that correlates with aortic mechanical properties.


Circulation | 2008

Circulating Markers of Abdominal Aortic Aneurysm Presence and Progression

Jonathan Golledge; Philip S. Tsao; Ronald L. Dalman; Paul Norman

Over the last decade abdominal aortic aneurysm (AAA) has increasingly been recognised as an important cause of mortality in older persons. In 1999 for example AAA was noted to be the 15th leading cause of mortality in the USA [1]. Exact estimates of AAA-related fatalities are hampered by the low rate of post-mortems when sudden death occurs in elderly subjects, however, recent figures suggest that AAA accounts for approximately 15,000 deaths annually in the USA despite the increasing numbers of elective AAA repairs [2,3]. Approximately 25,000 endovascular and open AAA repairs are performed annually in the USA [3]. Ultrasound screening of men >65 years has been demonstrated to reduce AAA-related mortality and selective screening (of men aged ≥65 who have ever smoked) has been introduced in the USA [4]. Most screen-detected AAAs are of small size (<55mm) and surgery for these AAAs has not been demonstrated to improve outcome [5-7]. In an screening study of 12,203 men ≥65 years performed in Australia for example, 814 (6.7%) had a small AAA measuring 30-54mm but only 61 (0.5%) a large AAA (≥55mm) [8]. The increase in identification of small AAAs resulting from screening programs, in association with an ageing population, will highlight the number of deficiencies in current diagnosis and management of this condition. Firstly, there are no accurate non-imaging methods of diagnosing small AAAs, with clinical examination being inaccurate [9]. Secondly, prognostic determinants for AAA are relatively poorly defined [10]. Approximately 70% of 40-55mm AAAs expand within 10 years to a size requiring treatment [6,7]. There are however large intra and inter-patient variations in rates of expansion of small AAAs during follow-up [10]. To date only initial aortic diameter has been consistently shown to predict subsequent increase in aortic diameter [10-13]. Smoking has been associated with increased, and diabetes with decreased, AAA expansion in some, but not all studies [10-13]. More accurate prognostic predictors would offer the possibility of selecting patients for different management pathways rather than relying on aortic diameter alone [10]. Finally the management of small AAAs remains controversial despite randomised controlled trials indicating that open surgical repair of 40-55mm AAAs does not reduce mortality [6,7]. Many centres manage all AAAs ≤55mms conservatively. Estimates based on the UK small aneurysm trial support repeat imaging for 30-40, 41-45, 46-50 and 51-55mm AAAs at 24, 12, 6 and 3 monthly intervals respectively [10]. The increasingly utilisation of endovascular repair of AAA, with its lower peri-operative mortality, has been suggested as more appropriate management for small AAAs, particularly those in the 50-55mm range [14,15]. At present however no randomised controlled trial has been completed examining the outcome of endovascular repair of small AAAs, although one such study is expected to report soon [16]. The lack of any proven medical therapy for prevention of progression and rupture of AAAs represents an important challenge [17]. Only one randomised trial has examined the value of a medication (propranolol) for small AAAs in a cohort of reasonable size (>500 subjects) [18].


Journal of Clinical Investigation | 2012

Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development

Lars Maegdefessel; Junya Azuma; Ryuji Toh; Denis R. Merk; Alicia Deng; Jocelyn T. Chin; Uwe Raaz; Anke M. Schoelmerich; Azad Raiesdana; Nicholas J. Leeper; Michael V. McConnell; Ronald L. Dalman; Joshua M. Spin; Philip S. Tsao

MicroRNAs (miRs) regulate gene expression at the posttranscriptional level and play crucial roles in vascular integrity. As such, they may have a role in modifying abdominal aortic aneurysm (AAA) expansion, the pathophysiological mechanisms of which remain incompletely explored. Here, we investigate the role of miRs in 2 murine models of experimental AAA: the porcine pancreatic elastase (PPE) infusion model in C57BL/6 mice and the AngII infusion model in Apoe-/- mice. AAA development was accompanied by decreased aortic expression of miR-29b, along with increased expression of known miR-29b targets, Col1a1, Col3a1, Col5a1, and Eln, in both models. In vivo administration of locked nucleic acid anti-miR-29b greatly increased collagen expression, leading to an early fibrotic response in the abdominal aortic wall and resulting in a significant reduction in AAA progression over time in both models. In contrast, overexpression of miR-29b using a lentiviral vector led to augmented AAA expansion and significant increase of aortic rupture rate. Cell culture studies identified aortic fibroblasts as the likely vascular cell type mediating the profibrotic effects of miR-29b modulation. A similar pattern of reduced miR-29b expression and increased target gene expression was observed in human AAA tissue samples compared with that in organ donor controls. These data suggest that therapeutic manipulation of miR-29b and its target genes holds promise for limiting AAA disease progression and protecting from rupture.


Journal of Vascular Surgery | 1991

Duplex ultrasound criteria for diagnosis of splanchnic artery stenosis or occlusion

Gregory L. Moneta; Richard A. Yeager; Ronald L. Dalman; Ruza Antonovic; Lee D. Hall; John M. Porter

Mesenteric artery duplex scanning appears promising for detection of splanchnic artery stenosis or occlusion or both in patients with symptoms suggestive of chronic intestinal ischemia. However, no specific duplex criteria have been developed for detection of mesenteric artery stenosis. We obtained mesenteric artery duplex scans and infradiaphragmatic lateral aortograms in 34 patients to determine duplex criteria for mesenteric stenosis. Seventy percent or greater angiographic stenosis was present in 10 superior mesenteric arteries and 16 celiac arteries. Duplex scans were reviewed to determine if celiac artery and superior mesenteric artery ratios of peak systolic velocities and end-diastolic velocities to peak aortic systolic velocity, as well as celiac artery and superior mesenteric artery peak systolic velocities and end-diastolic velocities alone, could predict a greater than or equal to 70% angiographic stenosis or occlusion or both. The results obtained by use of receiver operator curves indicated peak systolic velocity alone was an accurate predictor of splanchnic artery stenosis. Specifically, a peak systolic velocity greater than or equal to 275 cm/sec in the superior mesenteric artery and greater than or equal to 200 cm/sec in the celiac artery or no flow signal (superior mesenteric artery and celiac artery) predicted a 70% to 100% stenosis with sensitivity, specificity, and positive predictive values of 89%, 92%, and 80% for the superior mesenteric artery. Similar values for the celiac artery were 75%, 89%, and 85%, respectively. End-diastolic velocities or calculated velocity ratios conveyed no additional accuracy in predicting splanchnic artery stenosis.


Science Translational Medicine | 2012

MicroRNA-21 Blocks Abdominal Aortic Aneurysm Development and Nicotine-Augmented Expansion

Lars Maegdefessel; Junya Azuma; Ryuji Toh; Alicia Deng; Denis R. Merk; Azad Raiesdana; Nicholas J. Leeper; Uwe Raaz; Anke M. Schoelmerich; Michael V. McConnell; Ronald L. Dalman; Joshua M. Spin; Philip S. Tsao

miR-21 modulates abdominal aortic aneurysm development by regulating cell proliferation and apoptosis within the aortic wall. miR-21, a Red Alert for AAA Abdominal aortic aneurysms (AAAs) constitute a major public health burden, with few treatment options. In this common condition associated with increased age, male gender, high blood pressure, and especially smoking, the major conduit vessel within the abdomen slowly enlarges and may rupture, often fatally. MicroRNAs are short molecules that can simultaneously regulate translation of multiple genes. One example, microRNA-21 (miR-21), has been shown to control gene expression patterns that influence a variety of cellular processes including maturation, migration, proliferation, and survival. In a new study, Maegdefessel et al. investigated the role of miR-21 in two well-established mouse models of AAA: one in which the aorta is exposed to enzymatic degradation of supporting tissue and another in which mice predisposed to vascular disease spontaneously form AAA in response to the peptide hormone angiotensin II. In both models, miR-21 expression increased within the aortic wall as the AAA developed. miR-21 was also elevated in samples of aorta from patients with AAA compared with healthy controls. Nicotine, the major constituent of tobacco, accelerated AAA growth in both mouse models and caused an even larger increase in miR-21 expression. This appeared to be a protective response because preventing an increase in miR-21 with an inhibitor increased AAA growth and rupture rates in both models. In contrast, exogenous supplementation of miR-21 slowed aneurysm growth and prevented rupture, even in the presence of nicotine. This was partly mediated through miR-21’s suppressive effects on the protein PTEN (phosphatase and tensin homolog). Cell culture studies demonstrated that inflammatory stimuli, known to influence AAA development, increased miR-21 expression. These results suggest that enhanced miR-21 expression is an endogenous response to pathological aortic dilation and may offer a new therapeutic pathway that could be targeted to treat AAA in patients. Identification and treatment of abdominal aortic aneurysm (AAA) remains among the most prominent challenges in vascular medicine. MicroRNAs are crucial regulators of cardiovascular pathology and represent possible targets for the inhibition of AAA expansion. We identified microRNA-21 (miR-21) as a key modulator of proliferation and apoptosis of vascular wall smooth muscle cells during development of AAA in two established murine models. In both models (AAA induced by porcine pancreatic elastase or infusion of angiotensin II), miR-21 expression increased as AAA developed. Lentiviral overexpression of miR-21 induced cell proliferation and decreased apoptosis in the aortic wall, with protective effects on aneurysm expansion. miR-21 overexpression substantially decreased expression of the phosphatase and tensin homolog (PTEN) protein, leading to increased phosphorylation and activation of AKT, a component of a pro-proliferative and antiapoptotic pathway. Systemic injection of a locked nucleic acid–modified antagomir targeting miR-21 diminished the pro-proliferative impact of down-regulated PTEN, leading to a marked increase in the size of AAA. Similar results were seen in mice with AAA augmented by nicotine and in human aortic tissue samples from patients undergoing surgical repair of AAA (with more pronounced effects observed in smokers). Modulation of miR-21 expression shows potential as a new therapeutic option to limit AAA expansion and vascular disease progression.


Surgery | 1998

Matrix metalloproteinase inhibition limits arterial enlargement in a rodent arteriovenous fistula model

Thomas A. Abbruzzese; Raul J. Guzman; Robert Martin; Calvin Yee; Christopher K. Zarins; Ronald L. Dalman

BACKGROUND We administered a specific, nonselective matrix metalloproteinase (MMP) inhibitor (RS-113,456) to examine the effect of MMP inhibition on flow-mediated arterial enlargement in a rodent arteriovenous fistula (AVF) model. METHODS Four groups of male Sprague-Dawley rats were created: sham (sham operated; n = 10), control (2.0 mm left common femoral AVF alone; n = 16), vehicle (AVF plus 0.5 mL vehicle orally twice a day; n = 20), and treatment (AVF plus 25 mg/kg RS-113,456 in 0.5 mL vehicle orally twice a day; n = 16). Heart rate, mean arterial pressure, and body weight were recorded on postoperative days 0, 7, 14, and 21. On day 21, AVF patency was confirmed, the infrarenal aorta and common iliac arteries were exposed, blood flow velocity and external diameter were measured, and wall shear stress (WSS) was calculated. Analysis was performed by paired, two-tailed Student t test, one-way analysis of variance, and the Bonferroni/Dunn procedure for post hoc testing. RESULTS Heat rate, mean arterial pressure, and weight did not vary at any time between groups. Aortic and left iliac diameter was larger in the AVF groups than in sham groups (P < .001), and control and vehicle groups were larger than treatment groups (P < .0001). Changes in aortic and left iliac flow were also significant (AVF was more than sham and control, and vehicle was more than treatment). No difference in aortic and left iliac artery velocity and WSS or right iliac diameter, velocity, flow, or WSS was observed between groups. CONCLUSIONS MMP inhibition diminishes flow-mediated arterial enlargement in the rat AVF model.

Collaboration


Dive into the Ronald L. Dalman's collaboration.

Researchain Logo
Decentralizing Knowledge